Evidence map›Paper›PMID 34244424›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Large age shifts in HIV-1 incidence patterns in KwaZulu-Natal, South Africa.

Adam Akullian, Alain Vandormael, Joel C Miller, Anna Bershteyn, Edward Wenger, Diego Cuadros, Dickman Gareta, Till Bärnighausen, Kobus Herbst, Frank Tanser

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
12.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Antiretroviral therapy blocks natural selection on protective and disease-susceptible HLA-B alleles in HIV-1 infection.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 5 countries.

Adam AkullianInstitute for Disease Modeling, Bill and Melinda Gates Foundation, Seattle, WA 98109; aakullian@idmod.org.ORCID 0000-0001-8247-2172
Alain VandormaelHeidelberg Institute for Global Health, Heidelberg University, 69120 Heidelberg, Germany.
Joel C MillerSchool of Engineering and Mathematical Sciences, La Trobe University, Melbourne, VIC 3086, Australia.ORCID 0000-0003-4426-0405
Anna BershteynDepartment of Population Health, New York University Grossman School of Medicine, New York, NY 10016.ORCID 0000-0002-6604-7093
Edward WengerInstitute for Disease Modeling, Bill and Melinda Gates Foundation, Seattle, WA 98109.
Diego CuadrosDepartment of Geography and Geographic Information Science, University of Cincinnati, Cincinnati, OH 45221.
Dickman GaretaAfrica Health Research Institute, KwaZulu-Natal 4001, South Africa.ORCID 0000-0002-4004-5655
Till BärnighausenHeidelberg Institute for Global Health, Heidelberg University, 69120 Heidelberg, Germany.
Kobus HerbstAfrica Health Research Institute, KwaZulu-Natal 4001, South Africa.
Frank TanserAfrica Health Research Institute, KwaZulu-Natal 4001, South Africa.ORCID 0000-0001-9797-0000
Africa Health Research Institute · ZAGates Foundation · USCentre for the AIDS Programme of Research in South Africa · ZAHeidelberg University · DELa Trobe University · AUNew York University · USUniversity of Cincinnati · USUniversity of the Witwatersrand · ZA

Funding

Causal Pathways to population health impact of HIV antiretroviral treatmentR01HD084233 · NICHD · UNIVERSITY OF KWAZULU-NATAL · PI BARNIGHAUSEN, TILL, TANSER, FRANK COURTENEY · 2015 to 2021
$2.3M
Can HIV Hot-Spots be eradicated? An intervention to decrease HIV transmission to young women in rural KwaZulu-Natal South AfricaR01AI124389 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI BARNIGHAUSEN, TILL, TANSER, FRANK COURTENEY · 2016 to 2020
$2.1M
NIAID NIH HHS R01 AI124389NICHD NIH HHS R01 HD084233Wellcome TrustWETP NIH HHS 201433/Z/16/Z
6 · The paper itself

Abstract

Recent declines in adult HIV-1 incidence have followed the large-scale expansion of antiretroviral therapy and primary HIV prevention across high-burden communities of sub-Saharan Africa. Mathematical modeling suggests that HIV risk will decline disproportionately in younger adult age-groups as interventions scale, concentrating new HIV infections in those >age 25 over time. Yet, no empirical data exist to support these projections. We conducted a population-based cohort study over a 16-y period (2004 to 2019), spanning the early scale-up of antiretroviral therapy and voluntary medical male circumcision, to estimate changes in the age distribution of HIV incidence in a hyperepidemic region of KwaZulu-Natal, South Africa, where adult HIV incidence has recently declined. Median age of HIV seroconversion increased by 5.5 y in men and 3.0 y in women, and the age of peak HIV incidence increased by 5.0 y in men and 2.0 y in women. Incidence declined disproportionately among young men (64% in men 15 to 19, 68% in men 20 to 24, and 46% in men 25 to 29) and young women (44% in women 15 to 19, 24% in women 20 to 24) comparing periods pre- versus post-universal test and treat. Incidence was stable (<20% change) in women aged 30 to 39 and men aged 30 to 34. Age shifts in incidence occurred after 2012 and were observed earlier in men than in women. These results provide direct epidemiological evidence of the changing demographics of HIV risk in sub-Saharan Africa in the era of large-scale treatment and prevention. More attention is needed to address lagging incidence decline among older individuals.

Indexed as

AdolescentAdultAge DistributionAge FactorsFemaleHIV-1HIV InfectionsHIV SeropositivityHumansIncidenceMaleMiddle AgedSex FactorsSouth AfricaYoung Adultage distributionantiretroviral therapyHIV incidenceHIV prevention

Identifiers

PMID34244424
PMCPMC8285891
OpenAlexW3178708027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.